RECENT PROGRESS IN NEW BIOMARKERS FOR PROSTATE CANCER DETECTION

Since prostate cancer is still the most frequent cancer in males, extensive research has been done to improve detection techniques, diagnosis, and treatment options. When combined with MRI targeted biopsies, PSA-based screening has shown encouraging results in improving diagnostic quality and lowering overdiagnosis. Current research on screening for prostate cancer Recent advancements in prostate cancer screening are reviewed here, with an emphasis on new genomic and molecular markers that may be useful for early detection, prognosis, and therapeutic targeting, such as circulating tumor cells (CTCs) and exosomal miRs. Research on immunotherapy strategies to enhance immune responsiveness is still underway. One such strategy is the use of DNA-based vaccines in conjunction with sipuleucel-T to treat patients with advanced or metastatic prostate cancer. Molecular markers like PCA3 and TMPRSS2. These markers hold great promise to enhance the specificity of diagnosing the condition in urines. In their advances, there remains the challenge of improved sensitivity of the biomarker; less overtreatment of patients, and promoting non-invasive diagnosis. They would alter prostate cancer practice in as much as these markers are instituted in clinical practices promising a more precise, focused approach to managing cases of prostate cancer and increasing better outcomes among the patient groups.